BIM
ANAB icon

Bogle Investment Management’s AnaptysBio ANAB Stock Holding History

Bogle Investment Management’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-16,868
Closed -$363K – 8
2020
Q4 		$363K Buy
+16,868
New +$410K 0.58% 91
2020
Q2 		– Sell
-39,500
Closed -$558K – 311
2020
Q1 		$558K Buy
39,500
+11,900
+43% +$180K 0.06% 195
2019
Q4 		$449K Buy
+27,600
New +$653K 0.04% 228

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bogle Investment Management's ANAB Position: Q1 2021 in Review

Bogle Investment Management sold out of AnaptysBio (ANAB) in Q1 2021, closing a stake of 16,868 shares — an estimated $363K sold.

Bogle Investment Management first reported a position in ANAB in Q4 2019 and held it in 3 quarters. The position peaked at $558K in Q1 2020. 122 funds tracked by Wall St. Rank hold ANAB as of Q1 2021.

  • Bogle Investment Management reported no remaining AnaptysBio position as of Q1 2021 after selling out during the quarter.
  • Bogle Investment Management sold 16,868 AnaptysBio shares in Q1 2021, an estimated $363K.
  • Bogle Investment Management first reported a position in AnaptysBio in Q4 2019 and held it in 3 quarters.
  • Bogle Investment Management's AnaptysBio position peaked at $558K in Q1 2020.
  • 122 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2021.

Based on Bogle Investment Management's 13F filing for Q1 2021.